The size of the European Burn Care Market has been calculated at USD 0.56 Billion in 2022. It is estimated to reach USD 0.76 Billion by the end of 2027, growing at a CAGR of 6.3% from 2022 to 2027.
Burn injuries present many challenges to a various range of health care professionals who encounter them worldwide. The European Burns association describes burning injury as a complex trauma needing multidisciplinary and continuous therapy.
Most companies focus on developing new products that help to reduce the cost of treatment. New product launches' strategy accounted for the largest share of the overall growth strategies mapped from 2020 to 2025. In Europe, almost 50% of patients with burn injuries were younger than 16 years and similar to that, 60% were male patients. Flames, scalds, and contact burns are the most dominant causes in the total population, but in children, scalds clearly are the most prevalent causes.
The Major factors that focus on the growth of the market are a rise in burns, growing Healthcare expenditure, favorable government initiatives, and growing awareness of treatment options. Favorable government initiatives in the UK are driving growth in Europe. The annual incidence of burns is 0.2 to 2.9/10,000 inhabitants, with a declining trend in time due to growing awareness in the usage of biologics and its substitutes.
This research report on the European Burn Care Market has been segmented and sub-segmented into the following categories:
By Extent of Damage:
Among these, the advanced burn care products segment is expected to hold the largest share of the market, Germany will have the highest share in the market during the forecast period. Simultaneously, the biologics segment is expected to witness the highest CAGR from 2020 to 2025, with the U.K witness the highest growth in the market. Among these, most patients are treated in outpatient clinics, and depending on the severity of the burn, the patients require inpatient treatment.
Key market participants leading the European Burn Care Market Profiled in the Report are Smith & Nephew plc (U.K.), Acelity L.P (U.S.), 3M Company (U.S.), Molnlycke Health Care (Sweden), Derma Sciences Inc.(U.S.), Medtronic (Ireland), Coloplast A/S (Denmark), Convatec Inc (U.K.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com